Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | METAP2 | P50579 | 13/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985688 | 0.87 | CYP3A4 (0.49) | ALDH1A1GAAHTTMETAP2METAP1 | |
| SCHEMBL4272722 | 0.83 | METAP2 (0.69) | METAP2 | |
| SCHEMBL3985666 | 0.83 | TP53 (0.48) | ALDH1A1GAAHTTMETAP2METAP1 | |
| SCHEMBL18299151 | 0.81 | ALDH1A1 (0.50) | ALDH1A1GAAHTTMETAP2KMT2A | |
| SCHEMBL3981261 | 0.80 | ALDH1A1 (0.58) | ALDH1A1GAAHTTMETAP2METAP1 | |
| SCHEMBL3986500 | 0.71 | METAP2 (1.00) | ALDH1A1GAAHTTMETAP2METAP1 | |
| SCHEMBL6570647 | 0.70 | MCL1 (0.54) | ALDH1A1GAAHTTMETAP2KMT2A | |
| SCHEMBL11138283 | 0.70 | AR (0.38) | ALDH1A1HPGD | |
| SCHEMBL31125442 | 0.70 | AR (0.38) | ALDH1A1HPGD | |
| SCHEMBL21865747 | 0.70 | RXFP1 (0.55) | ALDH1A1GAAHTTMETAP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1549613-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | Abbott Laboratories (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ALDH1A1 3463/4885GAA 1250/4885HTT 4102/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | ALDH1A1 3463/4885GAA 1250/4885HTT 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.